School of Medicine, Shandong University, Jinan, 250012, People's Republic of China.
Department of Neurosurgery, Provincial Hospital Affiliated to Shandong University, Jingwu Road 324, Jinan, 250021, People's Republic of China.
J Neurooncol. 2018 Aug;139(1):185-193. doi: 10.1007/s11060-018-2859-8. Epub 2018 Apr 26.
Treatment of recurrent high-grade gliomas (rHGG) has always been challenging. This study aimed to explore the treatment effect of quantitative dynamic susceptibility contrast perfusion-weighted imaging (DSC-PWI)-guided gamma knife radiosurgery (GKRS) on rHGG.
Between April 2014 and July 2016, 26 consecutive patients were treated by quantitative DSC-PWI-guided GKRS as salvage treatment for rHGG. The gross tumor volume (GTV) was defined as the high perfusion area on absolute cerebral blood volume maps, with a cutoff value of 22 ml/100 g. The clinical target volume (CTV) encompassed the GTV by 3 mm. Overall survival (OS) and progression-free survival (PFS) were calculated by the Kaplan-Meier method. Prognostic factors were tested by the log-rank (Mantel-Cox) test.
With a median follow-up of 32 months, the median PFS after GKRS was 8 months (95% CI [6, 12]); the 1- and 2-year survival rates were 30.8 and 11.5%, respectively. The median OS was 25.5 months (95% CI [18, 40]); the 1- and 2-year survival rates were 96.2 and 57.7%, respectively. Pathology grade and CTV were identified as prognostic factors for PFS. However, none of the parameters tested were independent prognostic factors for OS among these selected patients. No severe radiotoxicity was observed among all patients.
Quantitative DSC-PWI-guided GKRS is feasible for the treatment of rHGG and that these outcomes remain to be validated. Despite this, we think that carefully selected patients can benefit from this treatment method.
复发性高级别神经胶质瘤(rHGG)的治疗一直具有挑战性。本研究旨在探讨定量动态磁敏感对比灌注加权成像(DSC-PWI)引导下伽玛刀放射外科(GKRS)治疗 rHGG 的治疗效果。
2014 年 4 月至 2016 年 7 月,26 例连续患者接受了定量 DSC-PWI 引导的 GKRS 作为 rHGG 的挽救性治疗。肿瘤总体积(GTV)定义为绝对脑血容量图上的高灌注区,截断值为 22ml/100g。临床靶体积(CTV)包含 GTV 外扩 3mm。采用 Kaplan-Meier 法计算总生存期(OS)和无进展生存期(PFS)。采用对数秩(Mantel-Cox)检验对预后因素进行检验。
中位随访 32 个月后,GKRS 后的中位 PFS 为 8 个月(95%CI [6, 12]);1 年和 2 年生存率分别为 30.8%和 11.5%。中位 OS 为 25.5 个月(95%CI [18, 40]);1 年和 2 年生存率分别为 96.2%和 57.7%。病理分级和 CTV 是 PFS 的预后因素。然而,在这些选定的患者中,没有一个参数被确定为 OS 的独立预后因素。所有患者均未观察到严重的放射性毒性。
定量 DSC-PWI 引导的 GKRS 治疗 rHGG 是可行的,其结果仍有待验证。尽管如此,我们认为,经过仔细选择的患者可以从这种治疗方法中受益。